Clinical Trial

A 26-week Primary Treatment Phase, with 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of AfrezzaÂ® Versus Rapid-acting Insulin Analog Injections, Both in Combination with a Basal Insulin, in Pediatric Subjects with Type 1 or Type 2 Diabetes Mellitus

Study Status:

Not yet active

Contact Information:

(956) 362-2396

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The primary objective of this study is to demonstrate that the efficacy of Afrezza is noninferior to RAA injections, when both are in combination with a basal insulin, as measured by the change in HbA1c from baseline to Week 26 in pediatric subjects ≥4 and <18 years of age with T1DM or T2DM.

Information:

Principal Investigator	Surya N. Mulukutla, MD
Co-PI	Luis Cantu Jr.
Sponsor	MannKind Corporation
Type of Trial	Interventional

Contact Us For More Info Or To Apply

5323 S. McColl Rd., Edinburg, TX 78539

[email protected]

(956) 362-2390

Clinical Trial

A 26-week Primary Treatment Phase, with 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of AfrezzaÂ® Versus Rapid-acting Insulin Analog Injections, Both in Combination with a Basal Insulin, in Pediatric Subjects with Type 1 or Type 2 Diabetes Mellitus

Study Status:

Contact Information:

Study Purpose:

Information:

Useful Links

For Research Participants

About Us

News & Views